Neil Dhawan

Neil Dhawan is the Founder and CEO of Totus Medicines, where he focuses on combining small molecule design, structural biology, genetics, biochemistry, and cell biology to design new classes of drugs to target untreatable diseases. Prior to founding Totus Medicines, Neil co-founded Dual Therapeutics, a venture-backed biotechnol­ogy company developing the first phosphatase agonists for cancer patients. Neil co-invented and helped develop the lead drug program, small-molecule agonists of PP2A, which led to a collaboration deal with Bristol Myers Squibb valued at up to $225 million.

Previously, Neil developed the first rational drug discovery approach to target pseudokinases, a class of ​‘undruggable’ targets with broad roles in cancer, diabetes, Alzheimer’s disease, and aging.